Allopurinol Versus Simvastatin to Prevent Complications of Liver Cirrhosis
Status:
Not yet recruiting
Trial end date:
2025-01-30
Target enrollment:
Participant gender:
Summary
The study aims to compare the potential benefit of allopurinol versus simvastatin in reducing
the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular
carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on
parents' related quality of life.